KemPharm Gets FDA Orphan Drug Designation for Serdexmethylph

The FDA has granted the Orphan Drug Designation to serdexmethylphenidate, KemPharm’s proprietary prodrug of d-methylphenidate for the treatment of idiopathic hypersomnia

Related Keywords

United States , Travis Mickle , Drug Administration , Orphan Drug Designation , Drug Designation ,